We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“show the benefit of evolocumab in a high-risk primary prevention patient population, specifically with long-standing diabetes and other risk factors, many of whom undoubtedly had significant, although unmeasured, ASCVD burden”
“VESALIUS-CV is an important and practice-changing trial. It demonstrates that more intensive lipid lowering therapy earlier in the atherosclerotic disease process is better to reduce major cardiovascular events. This trial blurs the boundaries of distinction across the atherosclerosis continuum.”
“Although PCSK9 inhibitors had been shown to reduce the risk of atherosclerotic cardiovascular disease events among patients with previous myocardial infarction or stroke, this new trial has shown their clinical benefit in patients without previous myocardial infarction or stroke. With a longer follow up than earlier PCSK9 inhibitor trials … numerically fewer deaths were observed in the evolocumab group than in the placebo group. Although this result was not significant owing to the hierarchical testing approach, it is likely to reflect a true signal.”
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: